Posted in | News | Business | Events

Flow Sciences, Inc. Partners with Three Companies to Contain Lyophilization Process of New HPAPI

On December 19, 2018; Allan W. Ader, Ph.D. (Safebridge Consultants, Inc.), and Richard Hirsh, CIH (Nektar Therapeutics) conducted a presentation along with Allan Goodman, Ph.D. of Flow Sciences, Inc. (FSI).

The presentation detailed the performance validation process of a Flow Sciences enclosure which was designed to protect Nektar Therapeutics personnel during the freeze-drying of powdered High Potency Active Pharmaceutical Ingredients (HPAPI). The presentation outlined the collaborative validation of enclosure containment performance between factory acceptance testing and site acceptance testing.

Since the respiratory-toxicological impacts of the HPAPI were not yet analyzed, Nektar Therapeutics utilized Safebridge Consultants, Inc. resources to develop an Occupational Health Categorization (or exposure band) for the substance. Flow Sciences consulted with SP Scientific to design an enclosure that accommodated the size of the Virtis Advantage Pro as well as space necessary for the safe cleanup of product in the event of a spill. During factory acceptance testing, FSI empirically verified containment performance through surrogate powder testing. During site acceptance testing, enclosure performance was put to the test through respiratory exposure sampling during a catastrophic-spill simulation. Sampling results from surrogate powder testing and the spill simulation indicated sampled respiratory exposure concentrations to be lower than laboratory reporting limits.

In summary, the multi-corporate effort of the project resulted in successful containment of a Lyophilization process to a concentration result of 1 microgram HPAPI per cubic meter of air (1 ug/m3).

If you would like more information regarding this collaborative performance validation between manufacturer, industrial hygiene consulting firm, and client; please download a copy of the presentation at the following link: Case Study for Containment of High Potency Active Pharmaceutical Ingredients (HPAPI) in the Freeze Drying Process.

You may also contact Flow Sciences, Inc. via telephone at (800)-849-3429 or email at [email protected].

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Flow Sciences, Inc.. (2019, January 16). Flow Sciences, Inc. Partners with Three Companies to Contain Lyophilization Process of New HPAPI. AZoM. Retrieved on November 21, 2024 from https://www.azom.com/news.aspx?newsID=50227.

  • MLA

    Flow Sciences, Inc.. "Flow Sciences, Inc. Partners with Three Companies to Contain Lyophilization Process of New HPAPI". AZoM. 21 November 2024. <https://www.azom.com/news.aspx?newsID=50227>.

  • Chicago

    Flow Sciences, Inc.. "Flow Sciences, Inc. Partners with Three Companies to Contain Lyophilization Process of New HPAPI". AZoM. https://www.azom.com/news.aspx?newsID=50227. (accessed November 21, 2024).

  • Harvard

    Flow Sciences, Inc.. 2019. Flow Sciences, Inc. Partners with Three Companies to Contain Lyophilization Process of New HPAPI. AZoM, viewed 21 November 2024, https://www.azom.com/news.aspx?newsID=50227.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.